DOSSIERS
Hieronder vindt u een reeks artikelen die verband houden met het thema dat in deze sectie wordt behandeld. Deze content wordt aangeboden in de vorm van podcasts, interviews, video's, infographics,....
DEFINING LENALIDOMIDE-SENSITIVE AND/OR REFRACTORY - PATIENTS IN MULTIPLE MYELOMA MANAGEMENT
Video in which Prof. Mohamad Mohty, Sorbonne hospital St Antoine (Paris) explains the significance of lenalidomide in treating patients with multiple myeloma.
In the video he distinguishes between lenalidomide-sensitive and lenalidomide refractory patients.
VIDEO
PRODUCTEN
Dit gedeelte bevat informatie over onze producten die voor u van nut kunnen zijn.
NINLARO®
Pharmaceutical class : Proteasome Inhibitors (PI)
Active compound : Ixazomib
NINLARO, in combination with lenalidomide and dexamethasone, is the 1st and only reimbursed Oral PI-triplet combination.
NRd is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Available dosages & packagings :
- 3 x 4mg
- 3 x 3 mg
- 3 x 2.3mg